Study Finds Multi-Omic Breast Cancer Test Predicts Radiation Therapy Benefit
Data show the test can predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer.
Data show the test can predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer.
Researchers develop PIPscore using plasma proteomics to identify triple-negative breast cancer patients most likely to benefit from immunotherapy treatment.
A new peer-reviewed study confirms that Ibex Breast significantly enhances accuracy, speed, and efficiency of breast pathology evaluations.
Ibex has introduced advancements to its AI-powered platform, enhancing breast cancer diagnostics, improving algorithm accuracy, and more.
Read MoreMany breast cancer survivors who qualify for genetic testing are not receiving it, though those who do often discuss results with family.
Read MoreA new blood test can predict the recurrence of breast cancer in high-risk patients by detecting cancer DNA months or years before relapse.
Read MorePreciseDx will present findings on their AI-driven breast cancer recurrence prediction test at the 2024 ASCO Annual Meeting.
Read MoreThis collaborative study seeks to represent a significant step forward in digital pathology and oncology breast cancer research
Read MoreBio-Rad Laboratories launched its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ESR1 Mutation Detection Kit.Â
Read MoreBCI testing is reshaping treatment decisions for early-stage HR+ breast cancer patients by helping guide endocrine therapy choices.
Read MoreThe AidaBreast novel biosignature also predicts radiation therapy benefit for early-stage invasive breast cancer patients.
Read MoreFor patients with metastatic HR+ breast cancer, there may be no test more important than monitoring for an ESR1 mutation.
Read MoreScientists developed a saliva test that screens for breast cancer, which is showing promising results in experimental testing.
Read MoreThe commonly ordered biomarker test is used to guide doctor’s recommendations for patients with estrogen receptor-positive breast cancer.
Read MoreA new test uses AI to see whether a patient is positive for cancer as soon as detectable by mammogram or earlier, and before symptoms arise.
Read MoreThough breast cancer rates for men are much lower, it is estimated that in 2023, about 2,800 men will be diagnosed with breast cancer.
Read MoreExai Bio’s liquid biopsy platform can detect breast cancer at the earliest stages and the smallest tumor sizes using a standard blood sample.Â
Read MoreDNADX utilizes sequencing DNA data from tumor tissue or plasma circulating tumor DNA to classify breast cancer into four subtypes or clusters.
Read More